TQA2225
/ Ampsource Biopharma, Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 26, 2024
Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P2 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis
1 to 1
Of
1
Go to page
1